Picture loading failed.

Anti-SSTR2;CD3E therapeutic antibody (Pre-made Tidutamab biosimilar,Bispecific Mixed mAb and scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Tidutamab (formerly XmAb 18087) is a humanised, Fc domain-containing, bispecific monoclonal antibody targeting somatostatin receptor 2 (SSTR2) and a cytotoxic T-cell binding domain (CD3), being developed by Xencor, for the treatment of neuroendocrine tumours (NET) and gastrointestinal stromal tumours (GIST).

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-570-1mg 1mg 3090
GMP-Bios-ab-570-10mg 10mg 21890
GMP-Bios-ab-570-100mg 100mg 148000
GMP-Bios-ab-570-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-SSTR2;CD3E therapeutic antibody (Pre-made Tidutamab biosimilar,Bispecific Mixed mAb and scFv)
INN Name Tidutamab
TargetSSTR2;CD3E
FormatBispecific Mixed mAb and scFv
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa;Lambda
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusDiscontinued
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2018
Year Recommended2019
CompaniesICON;Xencor
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedGastrointestinal stromal tumours;Neuroendocrine tumours
Development Techna